| Jun 4 |
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
|
| Jun 4 |
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
|
| Jun 1 |
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
|
| Jun 1 |
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
|
| May 30 |
Teva wins FDA nod for new Austedo formulation
|
| May 30 |
FDA approves Teva Pharmaceuticals’ AUSTEDO XR for TD and HD chorea
|
| May 29 |
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)
|
